Ryoji Noyori

Ryoji Noyori (????) (born September 3, 1938) won the Nobel Prize in Chemistry in 2001.

Chemistry

Noyori is most famous for asymmetric hydrogenation using as catalysts complexes of rhodium and ruthenium, particularly those based on the BINAP ligand. Asymmetric hydrogenation of an alkene in the presence of ((S)-BINAP)Ru(OAc)2 is used for the commercial production of enantiomerically pure (97% ee) naproxen, used as an anti-inflammatory drug. The anti-bacterial agent levofloxacin is manufactured by asymmetric hydrogenation of ketones in the presence of a Ru(II) BINAP halide complex.

Related Topics:
Asymmetric hydrogenation - Catalyst - Complexes - Rhodium - Ruthenium - BINAP - Ligand - Hydrogenation - Alkene - OAc - Ee - Naproxen - Anti-inflammatory - Anti-bacterial - Levofloxacin - Ketone

~ ~ ~ ~ ~ ~ ~ ~ ~ ~

He has also worked on other asymmetric processes. Each year 400 000 tonnes of menthol are produced (in 94% ee) by Takasago International Co., using Noyori's method for isomerisation of allylic amines.

Related Topics:
Tonnes - Menthol - Ee - Takasago International - Isomerisation - Allylic - Amine

~ ~ ~ ~ ~ ~ ~ ~ ~ ~

More recently he and Jessop have developed an industrial process for the manufacture of N,N-dimethylformamide from hydrogen, dimethylamine and supercritical carbon dioxide in the presence of {{Ruthenium}}{{Chlorine}}2(PMe3)4 as catalyst.

Related Topics:
Jessop - Dimethylformamide - Hydrogen - Dimethylamine - Supercritical - Carbon dioxide - Me

~ ~ ~ ~ ~ ~ ~ ~ ~ ~